Havrdova E, et al. Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients With Relapsing Multiple Sclerosis in the OPERA I and OPERA II Trials. EAN 2017, PR1092.
Vergoeding selumetinib (Koselugo) voor kinderen met neurofibromatose type 1
mei 2024